Presentations at the Orlando meeting showed Byetta-treated patients were at no higher risk for renal or pancreatic problems than existing treatments — including, Merck’s oral Januvia and Novo Nordisk’s in-kind Victoza injection therapy. Ergo, with no new sense of urgency for Byetta use – all Amylin and Lilly accomplished was to provide additional motivation for physicians to prescribe challengers Januvia and Victoza….
Continue Reading ….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.